Adaptive Biotechnologies Corp (NASDAQ: ADPT)’s stock price has decreased by 0.00 compared to its previous closing price of 7.49. However, the company has seen a -3.04% decrease in its stock price over the last five trading sessions. globenewswire.com reported 2025-04-10 that SEATTLE, April 10, 2025 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the first quarter 2025 after market close on Thursday, May 1, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Is It Worth Investing in Adaptive Biotechnologies Corp (NASDAQ: ADPT) Right Now?
ADPT has 36-month beta value of 1.68. Analysts have mixed views on the stock, with 3 analysts rating it as a “buy,” 4 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for ADPT is 141.74M, and currently, short sellers hold a 7.14% ratio of that float. The average trading volume of ADPT on April 17, 2025 was 1.96M shares.
ADPT’s Market Performance
ADPT stock saw a decrease of -3.04% in the past week, with a monthly decline of -0.93% and a quarterly a decrease of 8.24%. The volatility ratio for the week is 7.85%, and the volatility levels for the last 30 days are 9.64% for Adaptive Biotechnologies Corp (ADPT). The simple moving average for the last 20 days is -4.79% for ADPT stock, with a simple moving average of 25.93% for the last 200 days.
Analysts’ Opinion of ADPT
Many brokerage firms have already submitted their reports for ADPT stocks, with Goldman repeating the rating for ADPT by listing it as a “Buy.” The predicted price for ADPT in the upcoming period, according to Goldman is $9 based on the research report published on March 21, 2025 of the current year 2025.
JP Morgan, on the other hand, stated in their research note that they expect to see ADPT reach a price target of $15. The rating they have provided for ADPT stocks is “Overweight” according to the report published on July 05th, 2023.
Scotiabank gave a rating of “Sector Outperform” to ADPT, setting the target price at $15 in the report published on January 05th of the previous year.
ADPT Trading at -4.88% from the 50-Day Moving Average
After a stumble in the market that brought ADPT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -16.87% of loss for the given period.
Volatility was left at 9.64%, however, over the last 30 days, the volatility rate increased by 7.85%, as shares sank -4.65% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -8.20% lower at present.
During the last 5 trading sessions, ADPT fell by -4.27%, which changed the moving average for the period of 200-days by +105.28% in comparison to the 20-day moving average, which settled at $7.86. In addition, Adaptive Biotechnologies Corp saw 24.94% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ADPT starting from ROBINS HARLAN S, who sale 1,698 shares at the price of $9.00 back on Mar 24 ’25. After this action, ROBINS HARLAN S now owns 1,279,524 shares of Adaptive Biotechnologies Corp, valued at $15,282 using the latest closing price.
Harlan Robins, the Officer of Adaptive Biotechnologies Corp, proposed sale 1,698 shares at $8.66 during a trade that took place back on Mar 24 ’25, which means that Harlan Robins is holding shares at $14,705 based on the most recent closing price.
Stock Fundamentals for ADPT
Current profitability levels for the company are sitting at:
- -0.86 for the present operating margin
- 0.58 for the gross margin
The net margin for Adaptive Biotechnologies Corp stands at -0.89. The total capital return value is set at -0.35. Equity return is now at value -62.41, with -26.57 for asset returns.
Based on Adaptive Biotechnologies Corp (ADPT), the company’s capital structure generated 0.31 points at debt to capital in total, while cash flow to debt ratio is standing at -1.07. The debt to equity ratio resting at 0.44. The interest coverage ratio of the stock is -13.36.
Currently, EBITDA for the company is -128.76 million with net debt to EBITDA at -0.32. When we switch over and look at the enterprise to sales, we see a ratio of 6.44. The receivables turnover for the company is 4.29for trailing twelve months and the total asset turnover is 0.33. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.89.
Conclusion
To put it simply, Adaptive Biotechnologies Corp (ADPT) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
